Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher After Analyst Upgrade

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price traded up 7.3% during mid-day trading on Thursday after Cantor Fitzgerald raised their price target on the stock from $25.00 to $30.00. Cantor Fitzgerald currently has an overweight rating on the stock. Capricor Therapeutics traded as high as $18.25 and last traded at $18.15. 216,121 shares changed hands during trading, a decline of 81% from the average session volume of 1,141,077 shares. The stock had previously closed at $16.91.

A number of other equities research analysts also recently issued reports on CAPR. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Maxim Group increased their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company’s stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Vanguard Group Inc. lifted its position in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $426,000. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics in the 1st quarter valued at approximately $40,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Trading Up 9.3 %

The stock has a market capitalization of $839.63 million, a PE ratio of -19.88 and a beta of 4.00. The company’s 50-day moving average is $14.63 and its 200 day moving average is $8.29.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.